News

Results from a double-blind phase III study of more than 300 gastrointestinal stromal tumors (GIST) patients resistant to or intolerant of the standard treatment, Gleevec (imatinib mesylate), showed

In a financial update for the first six months of its fiscal year, the UK biotech firm stated that its previous articulated goal of achieving profitability by 2008

The team’s analysis of four microRNAs (miRNA) found in the blood plasma of pancreatic cancer patients is proof of principle to further develop a blood test for this

In the study, eight of 33 patients with advanced, refractory cutaneous T-cell lymphoma (CTCL) experienced partial responses, the primary endpoint of the study. The most common side effects

A review compared the treatment responses of 1,177 patients from ten clinical trials in which Bexxar was used as either first-line, second-line, third-line, or fourth-line (or greater) treatment.

Results from an interim analysis of this study showed that the median progression-free survival was 11 months for patients treated with Avastin (bevacizumab) plus chemotherapy, compared to six

Pegasys (peginterferon alfa-2a) is now approved for both variations of the chronic hepatitis B virus – HBeAg-positive and HBeAg-negative. Pegasys was approved in 2002 by the FDA for

Study data showed that, after four years, 15% of women treated with Herceptin plus chemotherapy experienced disease recurrence, compared to 33% of women treated with chemotherapy alone. Preliminary

Femara (letrozole tablets) prolonged disease free survival by reducing the risk of recurrence an additional 19% over that offered by tamoxifen when used as initial treatment after surgery,